Related Experiment Video
Updated: Sep 28, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Supportive Oncodermatology in Pediatric Patients
Danny W Linggonegoro1, Hannah Song1, Jennifer T Huang1
1Boston Children's Hospital, Dermatology Program, 300 Longwood Avenue, Fegan 6, Boston, MA 02115, USA; Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA.
Abstract:
Cutaneous reactions to targeted therapies are varied and common. Pediatric dermatology literature is emerging on the specific types and prevalence of cutaneous reactions to targeted therapies that hone in on membrane-bound receptors, intracellular signaling targets, and antiangiogenesis agents, as well as targeted immunotherapies. Data regarding the timing, severity, and treatment algorithms are most plentiful for BRAF, MEK, and EGFR inhibitors.
Insights
Pediatric targeted therapy use is increasing, leading to diverse skin reactions. Research is growing on these reactions, especially for BRAF, MEK, and EGFR inhibitors, with more data on timing and treatment.
Area of Science:
- Pediatric dermatology
- Oncology
- Pharmacology
Background:
- Targeted therapies are increasingly used in pediatric oncology.
- These therapies can cause a variety of cutaneous reactions.
- Literature on pediatric-specific reactions is still developing.
Purpose of the Study:
- To review the emerging literature on pediatric cutaneous reactions to targeted therapies.
- To highlight the types, prevalence, and management of these reactions.
- To identify areas with the most available data.
Main Methods:
- Literature review of pediatric dermatology and oncology studies.
- Focus on targeted therapies including receptor, signaling, antiangiogenesis, and immunotherapy agents.
- Analysis of data on reaction timing, severity, and treatment.
Main Results:
- Cutaneous reactions to targeted therapies are common and diverse in children.
- Emerging data covers various targeted agents, with most information available for BRAF, MEK, and EGFR inhibitors.
- Specific details on timing, severity, and treatment algorithms are most abundant for these inhibitors.
Conclusions:
- Pediatricians and dermatologists must be aware of potential skin toxicities from targeted cancer drugs.
- Further research is needed to fully characterize and manage all types of drug-induced skin reactions in children.
- Standardized data collection on reaction characteristics is crucial for developing optimal treatment guidelines.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Papillary Dermis
The dermis might be considered the "core" of the integumentary system, as distinct from the epidermis and hypodermis. It contains blood and lymph vessels, nerves, and other structures, such as hair follicles and sweat glands. The dermis is made of two layers of connective tissue that comprise an interconnected mesh of elastin and collagenous fibers, produced by fibroblasts.
Papillary Layer
The papillary layer is made of loose, areolar connective tissue, which means the collagen...
Clinical Applications of Epidermal Stem Cells
Changes in Skin Color: Clinical Perspectives
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Assessment of Airway, Skin Color, and Use of Accessory Muscles
Introduction
The initial evaluation of a patient's respiratory system...

